Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 250-page biotech filing that dives into modifier gene therapy science, vaccine partnerships, and burn-rate math can feel overwhelming. Ocugen鈥檚 disclosures are especially dense鈥攅very 10-K footnote, 8-K clinical update, and Form 4 trade may hint at the company鈥檚 cash runway or FDA progress. Stock Titan distills these complexities instantly.
Our AI engine turns the full spectrum of Ocugen SEC filings into plain English summaries. Compare R&D expenses quarter-over-quarter in the latest Ocugen quarterly earnings report 10-Q filing, track Ocugen insider trading Form 4 transactions minutes after they hit EDGAR, and see red-lined changes when an 8-K amends pivotal trial data. You鈥檒l find:
- AG真人官方-time alerts for Ocugen Form 4 insider transactions real-time and executive stock grants.
- Concise overviews of every Ocugen annual report 10-K simplified鈥攃ash burn, pipeline timelines, and risk factors without the jargon.
- Side-by-side charts that make Ocugen earnings report filing analysis effortless.
- Quick answers to 鈥�Ocugen proxy statement executive compensation鈥� or 鈥�Ocugen 8-K material events explained.鈥�
Whether you鈥檙e monitoring Ocugen executive stock transactions Form 4 before data readouts or simply understanding Ocugen SEC documents with AI, Stock Titan keeps you ahead with expert commentary, historical context, and full-text search across every form. Spend less time decoding biotech language and more time making informed decisions.
Ocugen, Inc. (NASDAQ: OCGN) has filed a Form 144 indicating a planned insider sale. The notice covers the potential disposition of 112,205 common shares鈥攁产辞耻迟 0.04 % of the 292.0 million shares outstanding鈥攖丑谤辞耻驳丑 Morgan Stanley Smith Barney LLC. The aggregate market value of the planned sale is $122,886.92, implying a reference price near $1.10 per share. The seller acquired the shares on 07/09/2025 via stock-option exercise and intends to sell on or after the same date on the NASDAQ exchange. No other sales were reported in the past three months. By signing the form, the filer asserts there is no undisclosed material adverse information regarding Ocugen.
The filing signals a modest insider liquidity event rather than a strategic transaction; the size is immaterial relative to float and should have limited market impact under normal trading volumes.
Citigroup Global Markets Holdings Inc., guaranteed by Citigroup Inc., is offering three-year Digital Notes linked to the worst performer of the S&P 500 (SPX) and Russell 2000 (RTY) indices. The notes are scheduled to price on July 31 2025 and mature on August 3 2028. At maturity investors will receive:
- $1,000 principal + a digital return of at least $210 (鈮�21%) if the worst-performing index closes at or above its initial level.
- Only the $1,000 principal if the worst performer closes below its initial level.
The notes pay no periodic interest, are not listed, and may trade at values below the issue price before maturity. Key risks highlighted include limited upside (capped at the digital return), dependence on a single valuation date, lack of dividends, index correlation risk, small-cap exposure via RTY, potential liquidity constraints, and the credit risk of Citigroup Global Markets Holdings Inc. and Citigroup Inc.
Ocugen has announced a significant merger agreement between its wholly-owned subsidiary OrthoCellix (holding Neocart product assets) and Carisma Therapeutics. The merger will result in OrthoCellix becoming a wholly-owned subsidiary of Carisma, with the following key terms:
- Ownership structure: Ocugen and concurrent investors will own approximately 90% of the combined company, while pre-merger Carisma stockholders will own 10%
- Valuation: OrthoCellix valued at $135 million (subject to adjustment), Carisma at $15 million
- Concurrent Investment: Minimum $25 million investment planned, with Ocugen committing at least $5 million
- Board composition: 6 members total - 5 designated by OrthoCellix, 1 by Carisma
The deal includes termination fees ($500,000 from Carisma or $750,000 from OrthoCellix under specific conditions), lock-up agreements, and CVRs for pre-merger Carisma stockholders. The merger is subject to stockholder approval, Nasdaq listing requirements, and other customary closing conditions.
FAQ
What is the current stock price of Ocugen (OCGN)?
What is the market cap of Ocugen (OCGN)?
What is Ocugen Inc.'s primary focus?
How does Ocugen differentiate its therapy approach?
Which disease areas are targeted by Ocugen鈥檚 clinical pipeline?
What are the key technological platforms used by Ocugen?
How does Ocugen ensure its scientific and clinical credibility?
What regulatory achievements has Ocugen attained?
Is Ocugen involved in any vaccine development projects?
How does Ocugen address unmet patient needs?
